February 13, 2025 05:13 AM ESTUpdated 06:23 AM

Hunger-suppressing biotech Aardvark raises $94M in IPO

Kyle LaHucik

Senior Reporter

Aardvark Therapeutics, a biotech looking to address hunger rather than appetite for metabolic diseases, will go public on Thursday with a $94 million debut on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Hunger-suppressing biotech Aardvark raises $94M in IPO

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Sanofi faces $250M charge after J&J-partnered vaccine flunks late-stage test

Kennedy is confirmed to lead HHS, putting anti-vaccine advocate and drug industry skeptic atop US health programs

After helping build AlphaFold, a 34-year-old first-time CEO launches his own AI biotech with $50M

Newleos, a new biotech with $93.5M, repurposes Roche's experimental CNS drugs

Neumora shakes up C-suite a month after depression drug fails first Phase 3 trial

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

Hunger-sup­press­ing biotech Aard­vark rais­es $94M in IPO

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Sanofi faces $250M charge af­ter J&J-part­nered vac­cine flunks late-stage test

Kennedy is con­firmed to lead HHS, putting an­ti-vac­cine ad­vo­cate and drug in­dus­try skep­tic atop US health pro­grams

Af­ter help­ing build Al­phaFold, a 34-year-old first-time CEO launch­es his own AI biotech with $50M

Newleos, a new biotech with $93.5M, re­pur­pos­es Roche's ex­per­i­men­tal CNS drugs

Neumo­ra shakes up C-suite a month af­ter de­pres­sion drug fails first Phase 3 tri­al

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

Hunger-suppressing biotech Aardvark raises $94M in IPO

Sanofi faces $250M charge after J&J-partnered vaccine flunks late-stage test

Kennedy is confirmed to lead HHS, putting anti-vaccine advocate and drug industry skeptic atop US health programs

After helping build AlphaFold, a 34-year-old first-time CEO launches his own AI biotech with $50M

Newleos, a new biotech with $93.5M, repurposes Roche's experimental CNS drugs

Neumora shakes up C-suite a month after depression drug fails first Phase 3 trial

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers